| Indicators | Browse All

Curis, Inc. (CRIS)

Healthcare | Biotechnology | Lexington, United States | NasdaqCM
0.60 USD -0.02 (-3.274%) ⇩ (Oct. 14, 2026, 4 p.m. EDT)
After hours: 0.60 +0.00 (0.834%) ⇧ (Oct. 14, 2026, 4:47 p.m. EDT)

Short-term:★☆☆☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 9:02 a.m. EDT

The immediate outlook is severely bearish as the stock has lost nearly 99.5% of its value over the last nine years, with the most recent annual performance showing another significant decline. While the current price sits near its five-year low, the technical picture remains precarious; the stock is trading well below both its 50-day and 200-day moving averages, indicating persistent downward pressure rather than a stabilization. The statistical forecast model predicts further downside over the next 45 days, though its very low confidence suggests this prediction is driven by extreme price volatility rather than a reliable trend. Fundamentally, the company is in deep distress, reporting negative operating margins, burning through cash, and carrying a forward P/E that implies negative earnings expectations. The balance sheet is fragile with a current ratio below 0.5 and substantial debt relative to equity. Despite a wide gap between the current price and the mean analyst target, the lack of analyst coverage and the deteriorating operational metrics suggest the market has already priced in a catastrophic failure of the business model. There is no dividend to provide income, and the capital structure appears unsustainable without a successful turnaround in the pipeline, which currently faces execution risks.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.491644
AutoARIMA0.808653
AutoETS0.808654
MSTL0.819865

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 26%
H-stat 14.95
Ljung-Box p 0.000
Jarque-Bera p 0.030
Excess Kurtosis -1.41
Attribute Value
Sector Healthcare
Debt to Equity Ratio 22.236
Revenue per Share 2.213
Market Cap 1,454,561
Trailing P/E 0.45
Forward P/E -0.10
Beta 3.10
Website https://www.curis.com

Info Dump

Attribute Value
52 Week Change -0.9799342
Address1 Building C
Address2 Suite 500 128 Spring Street
All Time High 54,500.0
All Time Low 0.59
Ask 1.29
Ask Size 1
Average Daily Volume10 Day 197,090
Average Daily Volume3 Month 202,415
Average Volume 202,415
Average Volume10Days 197,090
Beta 3.1
Bid 1.46
Bid Size 3
Book Value 2.409
City Lexington
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.5998
Current Ratio 0.492
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 0.6199
Day Low 0.58
Debt To Equity 22.236
Display Name Curis
Dividend Date 1,527,638,400
Dividend Yield 0.0
Earnings Call Timestamp End 1,778,617,800
Earnings Call Timestamp Start 1,778,617,800
Earnings Timestamp End 1,793,908,800
Earnings Timestamp Start 1,793,908,800
Ebitda -35,869,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.076
Enterprise To Revenue -0.636
Enterprise Value -2,743,707
Eps Current Year -23.77667
Eps Forward -6.01333
Eps Trailing Twelve Months 1.32
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.5204
Fifty Day Average Change -0.92060006
Fifty Day Average Change Percent -0.60549855
Fifty Two Week Change Percent -97.99342
Fifty Two Week High 33.6
Fifty Two Week High Change -33.0002
Fifty Two Week High Change Percent -0.9821488
Fifty Two Week Low 0.58
Fifty Two Week Low Change 0.019800007
Fifty Two Week Low Change Percent 0.034137946
Fifty Two Week Range 0.58 - 33.6
Financial Currency USD
First Trade Date Milliseconds 965,136,600,000
Float Shares 1,836,613
Forward Eps -6.01333
Forward P E -0.099745065
Free Cashflow -15,766,000
Full Exchange Name NasdaqCM
Full Time Employees 20
Fullday Change -0.0153000355
Fullday Change Percent -2.4673495
Fullday Price 0.6048
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -21,339,000
Has Pre Post Market Data 1
Held Percent Insiders 0.06455
Held Percent Institutions 0.29007998
Implied Shares Outstanding 2,425,078
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,783,296,000
Last Split Factor 1:20
Long Business Summary Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Long Name Curis, Inc.
Market us_market
Market Cap 1,454,561
Market State POST
Max Age 86,400
Message Board Id finmb_27159
Most Recent Quarter 1,782,777,600
Net Income To Common -21,153,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 2,308,431
Number Of Analyst Opinions 3
Open 0.619
Operating Cashflow -30,587,000
Operating Margins -8.33403
Payout Ratio 0.0
Phone 617 503 6500
Post Market Change 0.004999995
Post Market Change Percent 0.8336104
Post Market Price 0.6048
Post Market Time 1,792,010,830
Previous Close 0.6201
Price Eps Current Year -0.025226409
Price Hint 4
Price To Book 0.24898298
Price To Sales Trailing12 Months 0.33717224
Profit Margins 0.0
Quick Ratio 0.371
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.02030003
Regular Market Change Percent -3.2736704
Regular Market Day High 0.6199
Regular Market Day Low 0.58
Regular Market Day Range 0.58 - 0.6199
Regular Market Open 0.619
Regular Market Previous Close 0.6201
Regular Market Price 0.5998
Regular Market Time 1,792,008,001
Regular Market Volume 122,858
Return On Assets -0.93231004
Revenue Per Share 2.213
Sand P52 Week Change 0.17004645
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 2,425,078
Shares Percent Shares Out 0.074
Shares Short 179,462
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 168,213
Short Name Curis, Inc.
Short Percent Of Float 0.0746
Short Ratio 1.2
Source Interval 15
State MA
Symbol CRIS
Target High Price 65.0
Target Low Price 20.0
Target Mean Price 42.66667
Target Median Price 43.0
Total Cash 5,073,000
Total Cash Per Share 2.427
Total Debt 1,044,000
Total Revenue 4,314,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 1.32
Trailing P E 0.45439392
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 10.24425
Two Hundred Day Average Change -9.64445
Two Hundred Day Average Change Percent -0.94145006
Type Disp Equity
Volume 122,858
Website https://www.curis.com
Zip 2,421